The U.S. National Institutes of Health is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
Final data from Gilead Sciences Inc.’s antiviral drug remdesivir showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said.
Japan’s Takeda Pharmaceutical said on Friday an alliance of drugmakers the company spearheads enrolled the first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays.
Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19 […]
The European health regulator started reviewing data on AstraZeneca and Oxford University’s potential Covid-19 vaccine in real time, the first of such moves aimed at speeding up any approval process in the region for a vaccine.
Eli Lilly and Co. said the company’s rheumatoid arthritis drug baricitinib shortened the recovery time for hospitalized Covid-19 patients also given Gilead Sciences Inc.’s antiviral remdesivir.
U.S. hospitals have turned down about a third of their allocated supplies of the Covid-19 drug remdesivir since July as need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed.
The U.S. Food and Drug Administration expanded the emergency use authorization of Gilead Inc.’s experimental antiviral Covid-19 treatment remdesivir to allow the product’s use in all hospitalized Covid-19 patients.
Gilead remdesivir study finds only marginal benefit for moderate COVID-19 patients (Reuters) – Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc’s (GILD.O) […]
Gilead Sciences Inc. filed a marketing application with the U.S. Food and Drug Administration for the company’s experimental Covid-19 drug remdesivir.
